Corrigendum to Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study Ann Rheum Dis. 2023;82:1404-1414.
Publication Title
Annals of the rheumatic diseases
Document Type
Article
Publication Date
6-18-2025
Keywords
washington; swedish
Area of Special Interest
Orthopedics & Sports Medicine
Specialty/Research Institute
Orthopedics
Specialty/Research Institute
Dermatology
Specialty/Research Institute
Rheumatology
DOI
10.1016/j.ard.2025.05.013
COinS
